Trial Profile

A Phase Ib clinical proof of concept clinical trial assessing CTx001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTx 001 Complement Therapeutics (Primary)
Indications Dry age-related macular degeneration
Focus Adverse reactions

Most Recent Events

21 Apr 2023 New trial record
17 Apr 2023 According to Complement Therapeutics media release, the company announced the completion of a Euro 72 million Series A financing, With this new round of financing, CTx will continue the development and complete this Phase Ib clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com